Gefitinib NEW

Manufacturer Provide API Powder Antineoplastic Iressa CAS 184475-35-2 Gefitinib

Introduction

Product Name: Gefitinib

Other Name :N-(3-Chloro-4-fluoro-phenyl)-7-methoxy-6-(3-morpholin-4-ylpropoxy)quinazolin-4-amine                                                   Gefitinib

CAS NO:184475-35-2

Purity: 99%min
Appearance:White crystalline powder

Molecular formula:C22H24ClFN4O3

MW:446.9

Melting Pint :119-120°C

Boiling Point :586.8±50.0 °C(Predicted)

Density :1.322±0.06 g/cm3(Predicted)

Storage :Keep in dark place,Inert atmosphere,Room temperature

Gefitinib, is a drug used for certain breast, lung , and other cancers, also known as Iressa, a selective epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, for the treatment of prior locally advanced or metastatic non-chemical treatment or unsuitable for chemotherapysmall cell lung cancer (NSCLC).

Gefitinib is the first molecular targeted drug to be used in non-small cell lung cancer treatment. Epidermal growth factors (EGF) are a kind of polypeptide with a relative molecular mass of 6.45x103, and they can bind with epidermal growth factor receptors (EGFR) on target cell membrane surfaces to trigger biological effects. EGFR is a type of tyrosine kinase (TK) type receptor, so when bound with EGF, it will promote TK activation in the receptor. This will cause tyrosine residue in the receptor to autophosphorylate and send continuous dividing signals into the cell, causing cell proliferation and differentiation. EGFR is abundant in human tissue, and it is highly expressed in malign tumors.